Vibiosphen is a SME healthcare biotechnology in infectious diseases founded in 2014. Given the important and interdependent human, animal, and environmental dimensions of antimicrobial resistance, the One Health concept promotes a global effort to achieve the best health for people, animals, and the environment. In this context, Vibiosphen takes part of the efforts that are underway to develop new anti-infective therapies, to rejuvenate the antibiotic pipeline, develop novel antibiotics, and discover innovative therapeutic strategies for priority pathogens. Based on its pluridisciplinary and integrated approaches, Vibiosphen, with more than 7 years of expertise, offers support for the design of preclinical studies for the development of innovative solutions in the fight against infectious diseases. Vibiosphen is an innovative company which provides services for pre-clinical assessments of new therapies on a broad catalogue of mouse experimental models and in vitro predictive models from standard to custom-made models.
Looking for a particular Vibiosphen employee's phone or email?
Vibiosphen Questions
The Vibiosphen annual revenue was $1 million in 2026.
Patricia Martin is the Chief Scientific Officer of Vibiosphen.
7 people are employed at Vibiosphen.
Vibiosphen is based in Labège, Wallis and Futuna.
The NAICS codes for Vibiosphen are [5417, 54171, 54, 541, 541713].
The SIC codes for Vibiosphen are [87, 873].
Top Vibiosphen Employees
-
11
-
Célia Lecacheux
Pharmacologue at Vibiosphen
Toulouse, FR1
Related Companies
